Speaker Profile

Ph.D., CEO, Refuge Biotechnologies

Biography
Dr. Wang is the CEO of Refuge, a company he co-founded following nearly a decade of life science investment banking experience. He most recently served as director of healthcare investment banking at Barclays Capital, where he served as strategic financial advisor and helped raised capital for companies in the healthcare industry. Dr. Wang, a cancer survivor who is passionate about bringing forth “smarter” medicines that will transform cancer care, earned a B.S. in Applied Physics from Columbia University, an MBA from Columbia Business School, and a Ph.D. in Electrical Engineering from Princeton University.


Emerging Therapeutics Showcase:
Refuge Biotechnologies

Refuge is leveraging gene engineering technologies known as CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) to develop therapeutic cells that are programmed to make decisions inside the patient’s body.

Designing Intelligent Cell Therapies To Fight Cancer
Refuge Biotechnologies leverages synthetic biology technologies known as CRISPR Interference/activation to develop therapeutic cells programmed to make decisions inside a patient’s body.

 Session Abstract – PMWC Silicon Valley


The PMWC 2020 Emerging Therapeutics Showcase will provide a 15-minute time slot for selected companies and researchers in the CRISPR, Cell and Gene Therapy fields. Major advancements in safer cell- and gene-level editing technologies are bringing us closer toward cures for life-threatening disorders, from cancer to HIV to Huntington’s disease. Cell therapy, in which cellular material such as T cells capable of fighting cancer cells, is injected into a patient, has been demonstrated safe and effective. The popular new CRISPR tool that has been used to edit the genetic code of nearly any organism will have an enormous impact on human health. More than a dozen clinical trials employing CRISPR on human cells are already underway.